Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

LiDCO Extends Collaboration With BD

16 Apr 2009 07:00

RNS Number : 6366Q
LiDCO Group Plc
15 April 2009
 



Press Release 

16 April 2009

LiDCO Group Plc

("LiDCO" or "the Company")

LiDCO extends collaboration with BD

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, today has extended its exclusive collaboration with BD (Becton, Dickinson and Company)a leading global medical technology company dedicated to helping all people live healthy lives (see www.bd.com).

In June 2007, LiDCO signed an exclusive UK marketing collaboration with Becton, Dickinson U.K. LimitedLiDCO today announces the expansion of this exclusive collaboration with BD. Under the amended and restated terms of the agreement, LiDCO and BD will extend their exclusive marketing collaboration to include additional territories. The collaboration provides that BD Medical - Medical Surgical Systems regional sales teams will provide sales and marketing support for LiDCO products in territories additional to the UK. This marketing collaboration will result in an enhanced product offering for BD's customers as well as superior sales coverage for both LiDCO and LiDCO's network of distributors. 

In a separate agreement, LiDCO have entered an exclusive distribution and sales relationship for the LiDCOrapid Monitor with BD in Japan. This relationship will result in an enhanced product offering for BD customers, as well as improved access to LiDCO's technology by Japanese clinicians and patients. 

Dr Terry O'Brien, Chief Executive of LiDCO, commenting on the agreements stated: "This licensing arrangement in Japan and expansion of our marketing collaboration with a major corporation of the stature of BD further enhances our capabilities to provide our acute care customers with the best possible products and services to improve outcomes and reduce complications such as infections. We are very pleased to share a commitment with BD towards expanding access to innovative technologies that improve outcomes in the critically ill." 

Hideyuki Ashikaga, President, BD in Japan stated:

"BD designs and markets innovative products that address significant healthcare problems and deliver demonstrably higher benefits to patients, healthcare workers and researchers. Collaborating with LiDCO, an innovative company in an important healthcare market, will reinforce our capabilities to serve that market, in line with our corporate purpose of 'Helping all people live healthy lives'".

- ENDS -

For more information please contact:

LiDCO Group Plc

Terry O'Brien - Chief Executive

John Rowland - Company Secretary

Tel: +44 (0)20 7749 1500

www.lidco.com

FinnCap

Geoff Nash/ Stephen Norcross/

Marc Young 

+44 (0)20 7600 1658

www.finncap.com 

Media enquiries

Abchurch Communications

Heather Salmond / Stephanie Cuthbert / Simone Alves 

+44 (0)20 7398 7728

www.abchurch-group.com

About LiDCO Group Plc

LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's manufacturing facility is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. 

Early and rapid warning of change

Clear indication of therapeutic route: fluid or drug

Quantification of hemodynamic response, particularly stroke volume

Permits more effective delivery of fluids - the right amount at the right time

Advanced hemodynamic care has been shown to:

- Contribute to reduced morbidity and complications

- Reduce length of stay

- Reduce overall cost of care

* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors. 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase

LiDCO Distribution Network:

The Company sells direct to hospitals in the UK, and elsewhere predominantly through a worldwide network of specialty critical care and anesthesia distributors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIAMFTMMJBBML
Date   Source Headline
29th Mar 20167:00 amRNSRegulatory approval in China
24th Mar 20167:00 amRNSMaster distribution agreement & other distributors
15th Mar 20167:00 amRNSLaunching the new LiDCOunity at ISICEM Brussels
4th Mar 20164:31 pmRNSHolding(s) in Company
2nd Mar 20165:06 pmRNSBlock Listing Review
8th Feb 20167:00 amRNSTrading update
2nd Feb 20163:52 pmRNSHolding(s) in Company
23rd Nov 20157:00 amRNSMaster distribution agreement
16th Nov 20154:35 pmRNSDirector's Dealing
13th Oct 20158:30 amRNSUS purchasing agreement with US hospitals group
13th Oct 20157:00 amRNSHalf Yearly Report
23rd Sep 201510:03 amRNSNotice of Results
2nd Sep 20157:00 amRNSTrading update and notice of results
17th Aug 20157:00 amRNSFormal appointment of Chief Executive Officer
31st Jul 20157:00 amRNSBlock Listing Review
15th Jun 20152:27 pmRNSBoard appointment and grant of share options
11th Jun 20157:00 amRNSJapan reimbursement for LiDCOrapidv2 disposables
13th May 201511:45 amRNSResult of AGM
6th May 20157:01 amRNSCEO and Board Appointment
5th May 20151:32 pmRNSPosting of Annual Report & Notice of AGM
23rd Apr 20157:00 amRNSLiDCO data presented at London Forum
14th Apr 20157:00 amRNSHolding in Company
1st Apr 201512:49 pmRNSDirector/PDMR Shareholding
31st Mar 20157:01 amRNSLIDCOrapid v2 cleared for sale in Japan
31st Mar 20157:00 amRNSFinal Results
17th Mar 20157:00 amRNSShowcasing Portable LiDCO Stand System at ISICEM
10th Mar 20157:03 amRNSNotice of Results
2nd Mar 20156:14 pmRNSHolding(s) in Company
17th Feb 20157:00 amRNSFurther clinical support for LiDCOrapid
12th Feb 20157:00 amRNSTrading update and notice of results
30th Jan 201512:20 pmRNSBlock listing review
17th Dec 20142:39 pmRNSHolding(s) in Company
1st Dec 20142:39 pmRNSHolding(s) in Company
17th Nov 20147:00 amRNSFurther clinical support for LiDCOrapid
12th Nov 20145:15 pmRNSHolding(s) in Company
7th Nov 201412:03 pmRNSHolding(s) in Company
3rd Nov 20145:49 pmRNSHolding(s) in Company
16th Sep 20147:01 amRNSBoard Announcement
16th Sep 20147:00 amRNSHalf Yearly Report
21st Aug 201411:39 amRNSNotice of Results
18th Aug 20147:00 amRNSTrading update
31st Jul 20141:46 pmRNSBlock Listing Review
30th Jul 20147:00 amRNSFurther clinical support for LiDCO products
11th Jun 201412:45 pmRNSResult of AGM
11th Jun 201411:49 amRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
23rd May 20141:51 pmRNSPosting of Annual Report & Notice of AGM
22nd May 20144:01 pmRNSHolding(s) in Company
21st May 20147:00 amRNSMonitors Link with NantHealth's DeviceConX System
20th May 20147:00 amRNSResults of the OPTIMISE study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.